The protein synthesis production line: mechanisms and stress responses governing 'just-in-time' tRNA delivery to the ribosome

Lead Research Organisation: University of Aberdeen
Department Name: Sch of Medicine, Medical Sci & Nutrition

Abstract

The delivery of amino acids to the ribosome by the cellular tRNAs is central to the process of protein synthesis in every cell, and therefore to the use of the cell as a protein-producing 'factory' in biotechnology. In eukaryotes tRNA delivery is carried out by a GTP-requiring translation factor called eEF1, one of the most abundant proteins in the cell. eEF1 picks up amino-acid charged tRNAs and delivers them to the translating ribosome, with associated GTP hydrolysis. GDP on eEF1 is then exchanged for GTP by two other elongation factors called eEF1-beta and gamma, allowing the cycle to begin again.
The eEF1 proteins are crucially important; failure to deliver tRNA rapidly to the ribosome causes ribosome stalling on the mRNA, and binding of components of a ribosome quality control (RQC) pathway that triggers translation abandonment by the ribosome. This project will characterise new pathways that our lab has identified that resolve ribosomes stalled because of slow tRNA delivery by eEF1. We will use established assays for RQC stress responses, and off-pathway translation events such as misincorporation of amino acids or ribosomal frameshifting, to explore how the ribosome responds in 'empty ribosomal acceptor site' situations. The objective is to define the novel ribosomal stress response pathways that mediate cellular response to failed tRNA delivery.
Understanding how cells maintain amino acid-tRNA delivery to the ribosome (and avoid stress) while responding to environmental or biotechnological challenges is key to two of our most important industrial and medical challenges: optimising biotechnological expression of proteins and understanding human neurodevelopmental disease in which these processes are compromised. Biotechnology, for instance, uses gene expression to produce vaccines, pharmaceuticals and chemical feedstocks, but the resulting physiological challenge for a host organism is considerable because protein synthesis is one of the most energetically demanding processes in the cell, and production yields are often correspondingly compromised. To optimise recombinant protein expression, we must understand the management of demand on translation at the molecular level.
The PhD student will use advanced molecular biological methods including genome editing of the eEF1-tRNA delivery system and its associated eEF1-beta and gamma GTP recycling apparatus in yeast (Aberdeen lab) and mammalian cells (Edinburgh lab) to understand how the activity of this family of eEF elongation factors function to optimise protein synthesis in biotechnology, health and disease. This research project will also use a combination of synthetic biology and systems biology modelling, to understand how tRNAs are delivered to the ribosome, and the stress responses invoked when biotechnological expression of foreign proteins places excess demand on the systems. The synthetic circuit will be used to develop a biotechnologically-applicable novel feedback circuit that senses translational stress leading to vacant ribosome acceptor sites, and respond by reducing the protein synthetic rate to implement autogenous control of protein synthesis, thus reducing stalling in real-time. Full training in all aspects of molecular biology, systems and synthetic biology will be provided.

Publications

10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
BB/M016412/1 01/10/2015 30/09/2019
2282000 Studentship BB/M016412/1 01/10/2019 31/12/2023
 
Description This work aimed at understanding the molecular basis of some neurodevelopmental defects such as severe cases of epilepsy, autism and intellectual disability. Some of these conditions are caused by mutations in the protein eEF1A, the protein that delivers the tRNA to the ribosome during the elongation step of protein translation/assembly. It is then important to understand what kind of translation error these mutations cause to lead to the development of the before mentioned conditions. The data so far collected show that each mutation is responsible for either one or multiple translation errors (including incorporation of the wrong amino acid, inability to recognise the STOP signal during assembly, and premature termination), all leading the assembly of non-functional proteins. Investigation of possible drug targets is currently underway: this way it would be possible (in the future) for the treatment of the conditions seen in humans to be moved from treating the symptoms (for example: treatment of epileptic seizures) to the molecular cause. This would be important as not all people affected by the mutations investigated are responsive to the current standard of care.
Exploitation Route The current research might possibly lead to the investigation of more possible molecular targets for treatment, rather than symptoms related. In the long run, a better understanding of the biology behind these conditions could be achieved, alongside the potential to develop new medications.
Sectors Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology